UnitedHealth Drops Nearly 4% as Medicare Advantage Margin Fears and DOJ Overhang Return
UnitedHealth shares fell as investors refocused on Medicare Advantage profitability pressure, including the V28 risk-adjustment headwind and ongoing reimbursement uncertainty. The slide follows heightened regulatory overhang from active DOJ scrutiny into Medicare billing practices and broader political pressure on MA coding.
1. What’s moving the stock today
UnitedHealth Group (UNH) slid about 4% in the latest session, with the move largely driven by renewed investor concern over Medicare Advantage economics rather than a single earnings catalyst. The key pressure points remain reimbursement uncertainty and risk-adjustment changes (including the V28 transition) that have been widely cited as meaningful headwinds for 2026 performance, keeping sentiment fragile after the stock’s sharp drawdown earlier in 2026.
2. Regulatory and political overhang is back in focus
The stock’s weakness is also being amplified by persistent regulatory scrutiny tied to Medicare billing practices. UnitedHealth previously disclosed it began complying with formal criminal and civil requests from the Department of Justice, a backdrop that can keep multiples compressed as investors handicap potential remedies, restrictions, or settlement risk. Separately, a Senate report earlier in 2026 added to pressure around Medicare Advantage diagnosis-coding practices, reinforcing the perception of ongoing policy and enforcement risk.
3. Why the tape is sensitive at these levels
UNH has become highly reactive to Medicare-related headlines because 2026 is increasingly viewed as a reset year, with the market scrutinizing whether pricing, Stars performance, and cost controls can offset policy-driven revenue and margin headwinds. With the shares trading near multi-year lows, incremental negatives—especially anything that suggests tighter MA oversight or weaker payment dynamics—can trigger outsized day-to-day declines as positioning remains cautious.